J Obes Metab Syndr 2017; 26(4): 293-294
Published online December 30, 2017 https://doi.org/10.7570/jomes.2017.26.4.293
Copyright © Korean Society for the Study of Obesity.
Young-Jun Rhie1, and Kee-Hyoung Lee 2,*
1Department of Pediatrics, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea; 2Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
Correspondence to:
Kee-Hyoung Lee
Department of Pediatrics, Korea University Anam Hospital, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu,, Seoul 02841, Korea
Tel: +82-2-920-6604
Fax: +82-2-922-7476
E-mail: khlee218@kumc.or.kr
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fibroblast growth factor 21 (FGF21), a 210-amino-acid polypeptide hormone, is produced preferentially in the liver and regulates glucose and fat metabolism.1 Serum FGF21 has been suggested to be a possible biomarker for early detection of metabolic syndrome (MetS), type 2 diabetes mellitus (T2DM) and coronary heart disease in adults.2–4 But, few studies have investigated the correlation between FGF21 levels and metabolic parameters in children and adolescents. Our previous study5 evaluated the association between FGF21 and metabolic parameters in obese Korean children and adolescents and was published in
First, FGF21 was suggested as a surrogate marker for MetS and T2DM in adults.6,7 In this study, we found that FGF21 levels were higher in children with obesity or MetS than those without them. However, we could not show that the non-obese subjects with higher FGF21 levels had a higher risk for obesity or MetS later. This is a limitation of this cross-sectional study. Therefore, we suggest a longitudinal cohort study to identify the clinical role of FGF21 as a biomarker of MetS and T2DM in the pediatric population.
Second, for FGF21 to act as a biomarker for the early detection of MetS or T2DM, a reference range for age and sex is required. However, there has been no data for the reference range of FGF21 by age and sex. We suggest a multi-center study that includes more subjects from the general pediatric population is needed to document the reference range for FGF21 by age and sex. In the pediatric population, the pubertal stage should be also investigated for FGF21 reference range because pubertal stage can affect insulin resistance.
Finally, we thank you for the Letter and the opportunity to respond. We also hope that
Online ISSN : 2508-7576Print ISSN : 2508-6235
© Korean Society for the Study of Obesity.
Room 1010, Renaissance Tower Bldg., 14, Mallijae-ro, Mapo-gu, Seoul 04195, Korea.
Tel: +82-2-364-0886 Fax: +82-2-364-0883 E-mail: journal@jomes.org
Powered by INFOrang Co., Ltd